These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 36965526)
21. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990 [TBL] [Abstract][Full Text] [Related]
22. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients. Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723 [TBL] [Abstract][Full Text] [Related]
23. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model. Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A Antiviral Res; 2023 Jul; 215():105638. PubMed ID: 37207822 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5. Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136 [TBL] [Abstract][Full Text] [Related]
25. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2. Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549 [TBL] [Abstract][Full Text] [Related]
26. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1. Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604 [TBL] [Abstract][Full Text] [Related]
27. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720 [TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476 [TBL] [Abstract][Full Text] [Related]
29. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979 [TBL] [Abstract][Full Text] [Related]
30. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551 [TBL] [Abstract][Full Text] [Related]
31. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809 [TBL] [Abstract][Full Text] [Related]
32. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children. Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697 [TBL] [Abstract][Full Text] [Related]
33. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867 [TBL] [Abstract][Full Text] [Related]
34. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. Benotmane I; Velay A; Gautier-Vargas G; Olagne J; Obrecht A; Cognard N; Heibel F; Braun-Parvez L; Keller N; Martzloff J; Perrin P; Pszczolinski R; Moulin B; Fafi-Kremer S; Thaunat O; Caillard S Am J Transplant; 2022 Nov; 22(11):2675-2681. PubMed ID: 35713984 [TBL] [Abstract][Full Text] [Related]
37. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904 [TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H Front Immunol; 2023; 14():1170759. PubMed ID: 37180152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]